CLINICAL TRIALS PROFILE FOR NEXPLANON
✉ Email this page to a colleague
All Clinical Trials for Nexplanon
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01397097 ↗ | LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study | Completed | Bayer | Phase 3 | 2011-09-01 | The primary objective is to demonstrate that discontinuation rates in women (ages 18-35 years inclusive) using LCS12 are not higher than those seen in women using ENG subdermal implant over a period of 12 months. Secondary objectives are to observe the bleeding patterns, adverse event profiles and the occurrence of unintended pregnancies. Additionally, data on user satisfaction, IUS expulsions and implant site complications will be collected. |
| NCT01438736 ↗ | Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern? | Unknown status | Merck Sharp & Dohme Corp. | Phase 4 | 2011-09-01 | The purpose of the study is to examine how well three months preceding use of Cerazette progestin only pill predicts the bleeding pattern during following Nexplanon implant use. |
| NCT01438736 ↗ | Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern? | Unknown status | VL-Medi Oy | Phase 4 | 2011-09-01 | The purpose of the study is to examine how well three months preceding use of Cerazette progestin only pill predicts the bleeding pattern during following Nexplanon implant use. |
| NCT01767285 ↗ | Immediate vs. Delayed Postpartum Etonogestrel Implant | Completed | Duke University | Phase 4 | 2013-01-01 | The investigators are examining if there is a difference in continuation rates of the etonogestrel contraceptive implant between women who have the device placed immediately after delivery, before leaving the hospital, and women who have the device placed at the routine 6-week postpartum visit. There will be 60 subjects total, randomized in a 1:1 ratio, for 30 in each group. All participants will follow-up at the same postpartum clinic 6 weeks after delivery. They will then be contacted at 3, 6, and 12 months postpartum and asked to complete a brief survey. The investigators hypothesize that continuation rates of Implanon will be higher in the immediate postpartum placement arm than in the delayed placement arm. |
| NCT01873170 ↗ | Quantification of Immune Cells in Women Using Contraception (CHIC II) | Active, not recruiting | University of Pittsburgh | 2013-08-01 | This study is being done to understand if using birth control causes changes in the immune cells within the reproductive tract (including the cervix and the lining of the uterus) of healthy women. Immune cells are important because they help prevent infections from starting and help fight infections that have started. Immune cells are also the type of cells that HIV (human immunodeficiency virus) infects so understanding more about them will help to better understand how to prevent the spread of HIV. Immune cells will be studied from the reproductive tract of women who want to start using one of the following contraceptives: an oral contraceptive pill (COC), Depo-Provera (DMPA), the levonorgestrel IUD (Mirena®), the copper IUD (ParaGard®), or the etonogestrel subdermal implant (Nexplanon®).Immune cells will also be studied from the reproductive tract of women who are not using birth control and who are not at risk of pregnancy for comparison. | |
| NCT01920022 ↗ | Quickstart of Nexplanon® at Medical Abortion | Completed | Karolinska Institutet | Phase 4 | 2013-10-01 | Women having abortions are at high risk for subsequent unintended pregnancy and repeat abortion. Clearly, encouraging contraceptive use after abortion is a high priority. Long acting reversible contraceptives (LARCs, Implants and intrauterine contraception) are the most effective methods to help women avoid a repeat unwanted pregnancy and abortion. Studies in surgical abortion patients, show that "quickstart" of a LARC - i.e., inserting it during the surgical procedure - is associated with substantially greater use of that method six months later than requiring women to return later to get the device. However, today a majority of women chose medical abortion. The clinical routine is to insert LARCs at the follow up 2 to 3 weeks after the abortion treatment. Frequently women choose to do part of the abortion treatment at home and do not return for a follow up. Thus, the possibility to quick start a contraceptive method in medical abortion would be a major advantage especially if this could be done at the time of administration of mifepristone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Nexplanon
Condition Name
Clinical Trial Locations for Nexplanon
Trials by Country
Clinical Trial Progress for Nexplanon
Clinical Trial Phase
Clinical Trial Sponsors for Nexplanon
Sponsor Name
